Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
NCT03520790Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of paricalcitol oral solution in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Adverse Events at 2 years and Overall Survival at 2 years. Started Dec 2018; status: terminated.
02
Drugs
paricalcitol oral solution
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03520790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520790.